Prospects for correcting endothelial dysfunction with high doses of L-arginine in the prevention of cardiorenal complications: a focus on diabetes mellitus

Background. The current concept of cardiorenal metabolic syndrome involves the search for a single therapeutic target of intervention, specifically the functional state of the endothelium. Special attention is given to patients with diabetes mellitus (DM), who face the highest risks. The aim of the study was to analyze the literature data regarding endothelial function in type 2 DM and the role of high doses of L-arginine as a potential therapeutic requirement. Materials and methods. A literature search was conducted in the following databases: MEDLINE/PubMed, Web of Science, Scopus, Cochrane Library, and Google Scholar, encompassing studies published up to June 2026. The search was performed using the keywords: “L-arginine”, “cardiorenal metabolic syndrome”, “diabetes mellitus”, “efficacy”, “safety”. Results. Endothelial dysfunction (ED) is a well-known risk factor for the development of cardiovascular and cerebrovascular diseases, as well as diabetic nephropathy. Evaluating high doses of L-arginine as the sole endogenous substrate for ED correction represents a promising direction. Complex bioregulatory mechanisms (cofactor deficiency, decreased expression of NO synthase (NOS), or an excess of endogenous NOS inhibitors) necessitate discussion regarding the most effective doses of L-arginine in patients with diabetes mellitus and cardiorenal metabolic syndrome. Study results demonstrate significant improvements in ED, insulin secretion and sensitivity, glucose tole­rance, a reduction in inflammation, and a positive effect on lipid metabolism. Conclusions. ED is one of the key mechanisms driving the progression of cardiorenal complications in DM. The use of exogenous L-arginine possesses pathogenetically sound therapeutic potential, with high-dose therapy in the range of 6 to 12 g/day being clinically expedient — providing adequate substrate supply for the NO synthesis and matching the dosage range demonstrated as effective in clinical trials.

Authors

Institutions

Publication Details

Journal
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Published
2026-11-14
DOI
https://doi.org/10.22141/2224-0721.22.7.2026.1774
Primary Topic
Nitric Oxide and Endothelin Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prospects for correcting endothelial dysfunction with high doses of L-arginine in the prevention of cardiorenal complications: a focus on diabetes mellitus

M.M.M. Grechanyk, Olexandr V. Kuryata
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Nitric Oxide and Endothelin Effects
article

Prospects for correcting endothelial dysfunction with high doses of L-arginine in the prevention of cardiorenal complications: a focus on diabetes mellitus

M.M.M. Grechanyk, Olexandr V. Kuryata
article en

Abstract

Background. The current concept of cardiorenal metabolic syndrome involves the search for a single therapeutic target of intervention, specifically the functional state of the endothelium. Special attention is given to patients with diabetes mellitus (DM), who face the highest risks. The aim of the study was to analyze the literature data regarding endothelial function in type 2 DM and the role of high doses of L-arginine as a potential therapeutic requirement. Materials and methods. A literature search was conducted in the following databases: MEDLINE/PubMed, Web of Science, Scopus, Cochrane Library, and Google Scholar, encompassing studies published up to June 2026. The search was performed using the keywords: “L-arginine”, “cardiorenal metabolic syndrome”, “diabetes mellitus”, “efficacy”, “safety”. Results. Endothelial dysfunction (ED) is a well-known risk factor for the development of cardiovascular and cerebrovascular diseases, as well as diabetic nephropathy. Evaluating high doses of L-arginine as the sole endogenous substrate for ED correction represents a promising direction. Complex bioregulatory mechanisms (cofactor deficiency, decreased expression of NO synthase (NOS), or an excess of endogenous NOS inhibitors) necessitate discussion regarding the most effective doses of L-arginine in patients with diabetes mellitus and cardiorenal metabolic syndrome. Study results demonstrate significant improvements in ED, insulin secretion and sensitivity, glucose tole­rance, a reduction in inflammation, and a positive effect on lipid metabolism. Conclusions. ED is one of the key mechanisms driving the progression of cardiorenal complications in DM. The use of exogenous L-arginine possesses pathogenetically sound therapeutic potential, with high-dose therapy in the range of 6 to 12 g/day being clinically expedient — providing adequate substrate supply for the NO synthesis and matching the dosage range demonstrated as effective in clinical trials.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)Vol. 22(7)
Dnipro State Medical University (UA)
Nitric Oxide and Endothelin Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon